Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Toshiki Masuishi(Aichi Cancer Center), Fotios Loupakis(Istituti di Ricovero e Cura a Carattere Scientifico), Hisato Kawakami(Kindai University Hospital), Kensei Yamaguchi(The Cancer Institute Hospital), Tomohiro Nishina(Shikoku Cancer Center), Marwan Fakih(City Of Hope National Medical Center), Élena Elez(Vall d'Hebron Institute of Oncology), Javier Rodríguez(Clinica Universidad de Navarra), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Yoshito Komatsu(Hokkaido University Hospital), Taito Esaki(National Hospital Organization Kyushu Cancer Center), Ki Y. Chung(Prisma Health), Zev A. Wainberg(UCLA Medical Center), Andrea Sartore‐Bianchi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Kapil Saxena(Daiichi Sankyo (United States)), Eriko Yamamoto(Daiichi-Sankyo (Japan)), Emarjola Bako(Daiichi Sankyo (United States)), Yasuyuki Okuda(Daiichi-Sankyo (Japan)), Javad Shahidi(Daiichi Sankyo (United States)), Axel Grothey(West Cancer Center), Takayuki Yoshino(National Cancer Center Hospital East)
Cited by 408
Abstract
Related Papers
No related papers found
Powered by citation graph analysis